Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

S Durrant, AP Schwarer, KF Bradstock… - Internal medicine …, 2004 - Wiley Online Library
Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …
被引用次数：14 相关文章

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J Szer, S Durrant, A Schwarer, K Bradstock, J Gibson… - 2004 - digital.library.adelaide.edu.au
Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J Szer, S Durrant, AP Schwarer… - Internal medicine …, 2004 - pubmed.ncbi.nlm.nih.gov
Background Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

[引用][C] Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J SZER, S DURRANT, AP SCHWARER… - Internal medicine …, 2004 - pascal-francis.inist.fr
Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after
allogeneic bone marrow transplantation CNRS Inist Pascal-Francis CNRS Pascal and …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.

J Szer, S Durrant, AP Schwarer, KF Bradstock… - 2004 - cabidigitallibrary.org
Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.

J Szer, S Durrant, AP Schwarer… - Internal Medicine …, 2004 - search.ebscohost.com
Abstract Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone marrow
transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) disease …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.

J Szer, S Durrant, AP Schwarer… - Internal Medicine …, 2004 - europepmc.org
Background Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J Szer, S Durrant, AP Schwarer… - Internal Medicine …, 2004 - research.sahmri.org.au
Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J Szer, S Durrant, AP Schwarer, KF Bradstock… - Internal Medicine …, 2004 - elibrary.ru
Background: Prophylactic low dose iv ganciclovir in patients at risk after allogeneic bone
marrow transplantation (BMT) is highly effective in the prevention of cytomegalovirus (CMV) …

[引用][C] Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

J SZER, S DURRANT, AP SCHWARER… - Internal medicine …, 2004 - Blackwell